

Date: April 26, 2025

BSE Limited

Corporate Relationship Dept.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 532039

Integrated filing - Financial for the quarter and financial year ended March 31, 2025

Pursuant to the Securities and Exchange Board of India Circular dated December 31, 2024, read with relevant stock exchange circular, we are submitting herewith the Integrated Filing (Financial) for the quarter and financial year ended March 31, 2025, as follows:

- A) Financial Results – attached as Annexure A
- B) Statement on deviation/variation in utilisation of funds raised – Not Applicable
- C) Outstanding default on loans and debt securities – Not Applicable
- D) Related Party Transactions for the half year ended March 31, 2025 – attached as Annexure B

For Zenotech Laboratories Limited

(Abdul Gafoor Mohammad)
Company Secretary & Compliance Officer
ICSI Membership No. A22331

Encl: as above

Independent Auditor's Report on the Financial Results

To the Board of Directors of Zenotech Laboratories Limited

1. We have audited the accompanying Financial Results of **Zenotech Laboratories Limited** ("the Company") for the quarter and year ended 31 March 2025 ('the Statement'), being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").
Attention is drawn to note 4 of results of the Statement which states the reason for non-preparation of consolidated financial results.
2. In our opinion and to the best of our information and according to the explanations given to us, the statement:
 - a) is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, in this regard;
 - b) gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian accounting standards and other accounting principles generally accepted in India, of the net profit for the quarter and year ended and other comprehensive income and other financial information of the company for the quarter and year ended 31st March 2025.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Management's and Board of Directors' Responsibilities for the Financial Results

3. This Statement has been prepared on the basis of the audited financial statements for the year ended March 31, 2025.

The Company's Board of Directors are responsible for the preparation and presentation of these Financial Results that give a true and fair view of the net profit for the quarter and year ended and other comprehensive income and other financial information in accordance with Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgements and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy completeness of the accounting records, relevant to the preparation and presentation of the Financial Results that give a true and fair view and is free from material misstatement, whether due to fraud or error.

4. In preparing the Financial Results, the Board of Directors are responsible for assessing the Company's ability, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

5. Our objectives are to obtain reasonable assurance about whether the Financial Results as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Financial Results.



6. As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
- Identify and assess the risks of material misstatements of the Financial Results, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal controls.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under Section 143(3)(i) of the Act, we are also responsible for expressing our opinion through a separate report on the complete set of financial statements on whether the company has adequate internal financial controls with reference to financial statements in place and the operating effectiveness of such controls.
 - Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
 - Conclude on the appropriateness of the Management and the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Financial Results, including the disclosures, and whether the Financial Results represent the underlying transactions and events in a manner that achieves fair presentation.
7. We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter

8. Attention is drawn to the fact that the figures for the quarter ended 31st March 2025 and the corresponding quarter ended in the previous year as reported in these financial results are the balancing figures between audit figures in respect of full financial year and the published year to date unaudited figures up to the end of the third quarter of the relevant financial year which were subject to limited review by us. Our opinion is not modified in respect of this matter.

For **PKF Sridhar & Santhanam LLP**
Chartered Accountants
Firm Registration No. 003990S/S200018

KVNSS Viswanadh

Viswanadh VNSS Kuchi

Partner

Membership No. 210789

Place: Hyderabad

Date: 25th April 2025

UDIN: 25210789BM000Q4792



ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122

Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078

Phone:+91 90320 44584/585/586 Website: www.zenotechlab.com

Standalone Audited Financial Results for the Quarter and Year ended 31 March 2025

(Rs in lakhs, except share and per equity share data)

Sl. No.	Particulars	Quarter ended			Year ended	
		31.03.2025	31.12.2024	31.03.2024	31.03.2025	31.03.2024
		Audited*	Unaudited	Audited*	Audited	Audited
I	Revenue From Operations	1,111.32	1,022.16	808.96	3,897.57	3,676.15
II	Other Operating Income	101.77	101.79	101.79	407.14	407.16
III	Other Income	49.32	37.43	32.60	154.86	100.41
IV	Total Income (I+II+III)	1,262.41	1,161.38	943.35	4,459.57	4,183.72
V	Expenses					
	a). Cost of materials consumed	42.75	20.25	-	84.02	-
	b). Purchase of Stock-in-Trade	-	-	-	-	-
	c). Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-
	d). Employee benefit expenses	323.28	317.90	268.08	1,237.78	946.40
	e). Finance costs	-	-	-	-	-
	f). Depreciation and amortization expense	172.69	176.01	173.33	696.01	708.52
	g). Other Expenses	400.14	398.70	364.68	1,564.89	1,414.66
	Total expenses	938.86	912.86	806.09	3,582.70	3,069.58
VI	Profit/(Loss) before exceptional items and tax (IV-V)	323.55	248.52	137.26	876.87	1,114.14
VII	Exceptional items (Refer Note - 6)	(4.88)	62.40	-	192.32	-
VIII	Profit/(Loss) before tax (VI-VII)	318.67	310.92	137.26	1,069.19	1,114.14
IX	Tax expense					
	a). Current Tax	190.49	-	-	190.49	-
	b). Prior Period Tax	58.84	-	-	58.84	-
	c). Deferred Tax	(53.64)	141.64	71.31	258.57	284.27
	Total Tax Expense (IX)	195.69	141.64	71.31	507.90	284.27
X	Profit/(Loss) for the period (VIII-IX)	122.98	169.28	65.95	561.29	829.87
XI	Other Comprehensive Income					
	a). Items that will not be reclassified to Profit or Loss					
	Re - measurement of the defined benefit obligations	0.51	(0.96)	(7.19)	(2.37)	(3.84)
	b). Items that will be reclassified to Profit or Loss	-	-	-	-	-
	Less: Income Tax	(0.15)	0.28	1.85	0.69	1.12
	Total Other Comprehensive Income (a+b)	0.36	(0.68)	(5.34)	(1.68)	(2.72)
XII	Total Comprehensive Income for the period (X+/-XI)	123.34	168.60	60.61	559.61	827.15
XIII	Paid-up equity share capital (Face value of ₹ 10/- per share)	6,103.06	6,103.06	6,103.06	6,103.06	6,103.06
XIV	Reserves i.e. Other equity				3,510.02	2,951.10
XV	Earnings/ (loss) per share (of ₹ 10/- each) (not annualised)					
	a) Basic	0.20	0.28	0.11	0.92	1.36
	b) Diluted	0.20	0.28	0.11	0.92	1.36

* The figures for the quarter ended March 31, 2025 and March 31, 2024 are the balancing figure between the audited figures in respect of the full financial year and the unaudited published year to date figures up to the third quarter of the relevant financial year which were subject to limited review by the Statutory Auditor of the Company.

See accompanying notes to the financial results

ZENOTECH LABORATORIES LIMITED

CIN: L27100TG1989PLC010122


Survey No.250-252, Turkapally (V), Shameerpet (M), Hyderabad - 500078

Phone:+91 40 23480430 / 35 www.zenotechlab.com

Standalone Balance Sheet as at March 31, 2025

Rs in Lakhs

Particulars	As at	As at
	31 March 2025	31 March 2024
	Audited	Audited
ASSETS		
(1) Non Current Assets		
(a) Property, Plant and Equipment	6,086.73	6,558.13
(b) Capital Work-In-Progress	357.33	195.62
(c) Financial Assets		
(i) Investments	-	-
(ii) Others	144.74	138.19
(d) Deferred Tax Assets (net)	394.04	652.61
(e) Income Tax Assets	512.04	445.98
(f) Other Non-current Assets	9.23	13.83
Total Non - Current Assets	7,504.11	8,004.36
(2) Current Assets		
(a) Inventories	-	84.02
(b) Financial Assets		
(i) Trade Receivables	745.43	324.94
(ii) Cash and Cash Equivalents	2,657.51	181.57
(iii) Bank balances other than above	12.71	1,787.00
(iv) Other financial asset	119.62	160.01
(c) Other Current Assets	63.67	78.74
Total Current Assets	3,598.94	2,616.28
TOTAL ASSETS	11,103.05	10,620.64
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	6,103.06	6,103.06
(b) Other Equity	3,510.02	2,951.10
Total Equity	9,613.08	9,054.16
LIABILITIES		
(1) Non-current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	-
(ii) Other financial liabilities	87.98	80.01
(b) Other Non Current Liabilities	9.44	17.00
(c) Provisions	133.85	117.16
Total Non - Current Liabilities	231.27	214.17
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Trade payables		
(a) Total outstanding dues of Micro and Small Enterprises	61.65	6.50
(b) Total outstanding dues other than above	190.71	322.69
(ii) Other financial liabilities	283.15	281.20
(b) Other Current Liabilities	156.27	105.33
(c) Provisions	445.39	636.59
(c) Current tax Liabilities (net)	121.53	-
Total Current Liabilities	1,258.70	1,352.31
TOTAL EQUITY AND LIABILITIES	11,103.05	10,620.64



Zenotech Laboratories Limited

Standalone Cash flow statement for the Year ended March 31, 2025

Rs in Lakhs

	For the Year ended 31 March 2025	For the Year ended 31 March 2024
A. Cash flows from operating activities		
Profit/(loss) before taxation	1,069.19	1,114.14
Adjustments for:		
Depreciation and amortisation	696.01	708.52
Amounts written back	(194.01)	(1.16)
Unrealised foreign exchange loss, net	1.77	(0.54)
Profit on sale of Property , Plant and Equipment	-	4.37
Interest income	(140.90)	(94.51)
Operating cash flows before working capital changes	1,432.06	1,730.82
Changes in Working Capital:		
(Increase)/ decrease in trade receivables	(420.49)	7.41
(Increase)/ decrease in inventories	84.02	(84.02)
(Decrease)/ increase in trade payables	(75.14)	(17.33)
(Increase)/ decrease in other financial assets	40.39	(87.58)
(Increase)/ decrease in current non financial assets	-	-
(Increase)/ decrease in non-current financial assets	(6.55)	-
(Increase)/ decrease in non-current assets	4.60	-
(Increase)/ decrease in other current assets	15.07	19.36
(Decrease)/ increase in provisions	15.85	(179.55)
(Decrease)/ increase in other financial liabilities	1.95	(93.40)
(Decrease)/ increase in other current liabilities	50.94	(6.20)
Cash used in operations	1,142.70	1,289.51
Income taxes paid/ TDS (net)	(193.86)	(107.26)
Net cash used in operating activities (A)	948.84	1,182.25
B. Cash flows from investing activities		
Payment for Purchase of property plant equipment (Including Capital advance & Work in Progress)	(386.32)	(423.35)
Proceeds from sale of Property , Plant and Equipment	-	0.37
Deposits towards margin money	-	-
(Increase)/Decrease in other bank balances	1,774.29	(1,787.00)
Interest income received	140.90	94.51
Net cash provided by/ (used in) investing activities	1,528.87	(2,115.47)
C. Cash flows from financing activities		
Repayment of borrowings	-	-
Interest paid	-	-
Net cash provided by financing activities (C)	-	-
Net increase/ (decrease) in cash and cash equivalents during the year(A+B+C)	2,477.71	(933.22)
Cash and cash equivalents at the beginning of the year	181.57	1,114.24
Add/(less): exchange (loss)/gain on cash and cash equivalents	(1.77)	0.54
Cash and cash equivalents at the end of the year	2,657.51	181.57



Notes:

1. The above financial results for the quarter and year ended March 31, 2025 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on 25th April, 2025 and have undergone an audit by the Statutory Auditors of the Company.
2. These financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.
3. Majority of the matters relating to several financial and non-financial irregularities pertaining to period prior to November 12, 2011 were abated/settled. Accordingly, based on the steps taken by the Company and evidence available so far, the Company believes that the financial impact if any, with respect to those legacy matters, on the results of the Company is not material.
4. The Company's overseas subsidiaries namely Zenotech Farmaceutica Do Brasil Ltda (Zenotech-Brazil) and Zenotech Inc (Zenotech-USA) were defunct and reported as cancelled/revoked respectively based on the Registration Cancellation certificate dated 8th June 2022 and Long Form Standing certificate dated 15th June 2022 respectively, received from the concerned authorities. Winding up order for Zenotech Laboratories Nigeria Limited has been received during FY: 2019-20. However, related filings with RBI is pending. Accordingly, the Company is of the view that it does not have subsidiaries, joint ventures and associates within the definition of Ind AS 110 and hence consolidated financial statements/Results are no longer applicable.
5. Other operating income relates to rentals for the Biotech facility and equipment leased to Sun Pharmaceutical Industries Limited for R&D activities.
6. During FY 2023-24, the Company registered under the Amnesty Scheme for a one-time settlement of export obligation defaults under the "Advance Authorization and EPCG Scheme" as notified by DGFT. Out of 14 EPCG licenses approved under the scheme, 10 licenses were settled in the previous quarters and another 2 in the current quarter. Accordingly, the Company provided ₹4.88 lakhs in the current quarter (₹197.20 lakhs up to previous quarter), bringing the total reversal to ₹192.32 lakhs for the year ended 31st March 2025. This reversal, following the crystallization of liability, has been reported as an Exceptional Item and the process is in progress for balance 2 licenses. The balance provision carrying in the books as on 31st March 2025 amounts to ₹ 422.10 lakhs.
7. The Company has only one segment, i.e. Pharmaceuticals.
8. Figures for previous period/ year have been regrouped to conform to the current period presentation.

By Order of the Board



Chairman of the Board meeting
Dr. Azadar Husain Khan
DIN: 01219312

Place: New Delhi
Date: 25 April, 2025



CIN: L27100TG1989PLC010122
ZENOTECH LABORATORIES LIMITED
Registered Office & Factory:
Survey No.250 -252
Turkapally Village
Shamirpet Mandal
Hyderabad - 500 078 T.S., India.
Tel: +91 90320 44584/ 585
Email: info@zenotech.co.in
www.zenotechlab.com

Date: April 25, 2025

BSE Limited
Corporate Relationship Dept.,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001

Scrip Code: 532039

Dear Sir/ Ma'am,

Sub: Declaration under Regulation 33(3)(d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

I, Poly K.V., Chief Financial Officer of Zenotech Laboratories Limited, having registered office at Survey No.250-252, Turkapally Village, Shameerpet Mandal, Hyderabad – 500 078, hereby declare that the Statutory Auditors of the Company, M/s. PKF Sridhar & Santhanam LLP, Chartered Accountants (Firm Registration No. 003990S/S200018) have issued an Audit Report with unmodified opinion on the Audited Standalone Financial Results of the Company for the financial year ended March 31, 2025.

Kindly take this declaration on your record.

Yours faithfully,
For **Zenotech Laboratories Limited**

Poly K.V.
Chief Financial Officer

FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS OF ZENOTECH LABORATORIES LIMITED FOR THE HALF YEAR ENDED MARCH 31, 2025

Amount in (Lakhs)

Sr. No.	Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																			
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments						
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary	Nature of indebtedness (loan/ issuance of debt/ any other etc.)								Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)	Notes
1	Zenotech Laboratories Limited	Sun Pharmaceutical Industries Limited	Holding Company	Sale of goods or services		5,000.00	Approved	5,000.00	01-05-2024	2,133.48	745.43	745.43	Not Applicable							
2	Zenotech Laboratories Limited	Poly.K.V	KMP	Remuneration		26.69	Approved	26.69	01-05-2024	12.83	0	0								
3	Zenotech Laboratories Limited	Abdul Gafoof Mohammad	KMP	Remuneration		23.36	Approved	23.36	01-05-2024	11.2	0	0								
4	Zenotech Laboratories Limited	Dr.Sachin Laxmanappa Gavandare	KMP	Remuneration		52.04	Approved	52.04	23-10-2024	22.65	0	0								
5	Zenotech Laboratories Limited	Sun Pharmaceutical Industries Limited	Holding Company	Any other transaction	Reimbursement of expenses	800	Approved	800	01-05-2024	392.16	0	0								
6	Zenotech Laboratories Limited	Sun Pharmaceutical Industries Limited	Holding Company	Any other transaction	Security deposit	0	Approved	0	01-05-2024	0	108.94	108.94								
7	Zenotech Laboratories Limited	Sun Pharmaceutical Industries Limited	Holding Company	Any other transaction	Deferred revenue	0	Approved	0	01-05-2024	174.27	43.57	43.57								
8	Zenotech Laboratories Limited	Kavita Rakesh Shah	Director	Any other transaction	Sitting fees	1	Approved	1	23-10-2024	0.55	0	0								
9	Zenotech Laboratories Limited	Jignesh Anantray Goradia	Director	Any other transaction	Sitting fees	1	Approved	1	23-10-2024	0.55	0	0								
10	Zenotech Laboratories Limited	Chintan Jitendra Shah	Director	Any other transaction	Sitting fees	1	Approved	1	23-10-2024	0.55	0	0								
11	Zenotech Laboratories Limited	Jagruti Prashant Sheth	Director	Any other transaction	Sitting fees	1	Approved	1	23-10-2024	0.55	0	0								
12	Zenotech Laboratories Limited	Sun Pharmaceutical Industries Limited	Holding Company	Any other transaction	Leases	500	Approved	500	01-05-2024	199.79	0	0								
Total value of transaction during the reported period										2,948.58										